MediPharm Labs Extends Strategic Partnership with ADREXpharma and continues to Build its Presence in Germany
Retrieved on:
Tuesday, June 8, 2021
MediPharm and ADREX pioneered and progressed German regulatory acceptance of EU GMP cannabis API and finished dosed products from Canada and Australia.
Key Points:
- MediPharm and ADREX pioneered and progressed German regulatory acceptance of EU GMP cannabis API and finished dosed products from Canada and Australia.
- With our global platform purpose built to good manufacturing practices, MediPharm has established a strong foothold in the nascent, but burgeoning, German cannabis market, said Keith Strachan, President and Interim CEO, MediPharm.
- Our collaboration with ADREX has been an important and strategic step in our growth in this attractive market.
- Our mission is to serve and offer the best therapeutical options to all patients in need in Germany.